160 related articles for article (PubMed ID: 30642841)
21. Development and validation of a tobacco smoking-related index for predicting overall survival and immunotherapy response in bladder cancer.
Liu F; Han Z; Lu J; Zhong W
Environ Sci Pollut Res Int; 2023 Jun; 30(26):68701-68715. PubMed ID: 37129813
[TBL] [Abstract][Full Text] [Related]
22. A potential prognostic lncRNA signature for predicting survival in patients with bladder urothelial carcinoma.
Bao Z; Zhang W; Dong D
Oncotarget; 2017 Feb; 8(6):10485-10497. PubMed ID: 28060759
[TBL] [Abstract][Full Text] [Related]
23. A panel of eight-miRNA signature as a potential biomarker for predicting survival in bladder cancer.
Zhou H; Tang K; Xiao H; Zeng J; Guan W; Guo X; Xu H; Ye Z
J Exp Clin Cancer Res; 2015 May; 34(1):53. PubMed ID: 25991007
[TBL] [Abstract][Full Text] [Related]
24. Expression signature defined by FOXM1-CCNB1 activation predicts disease recurrence in non-muscle-invasive bladder cancer.
Kim SK; Roh YG; Park K; Kang TH; Kim WJ; Lee JS; Leem SH; Chu IS
Clin Cancer Res; 2014 Jun; 20(12):3233-43. PubMed ID: 24714775
[TBL] [Abstract][Full Text] [Related]
25. Clinical and RNA expression integrated signature for urothelial bladder cancer prognosis.
Xiong J; Xiong K; Bing Z
Cancer Biomark; 2018 Feb; 21(3):535-546. PubMed ID: 29226853
[TBL] [Abstract][Full Text] [Related]
26. Assessment of Plasma Amino Acid Dynamics in Response to ACTH Stimulation by Liquid Chromatography Tandem-Mass Spectrometry.
Paal M; Lindner JM; Schmoeckel P; Suhr AC; Schafferer S; Koal T; Briegel J; Vogeser M
Clin Lab; 2018 Oct; 64(10):1695-1700. PubMed ID: 30336519
[TBL] [Abstract][Full Text] [Related]
27. Study on bladder cancer susceptibility and genetic polymorphisms of XPC, XPG, and CYP in smokers and non-smokers.
Wen H; Feng CC; Fang ZJ; Xia GW; Jiang HW; Xu G; Huang XD; Ding Q
Actas Urol Esp; 2013 May; 37(5):259-65. PubMed ID: 23246108
[TBL] [Abstract][Full Text] [Related]
28. Metabolomic profile of neuroendocrine tumors identifies methionine, porphyrin, and tryptophan metabolisms as key dysregulated pathways associated with patient survival.
La Salvia A; Lens-Pardo A; López-López A; Carretero-Puche C; Capdevila J; Benavent M; Jiménez-Fonseca P; Castellano D; Alonso T; Teule A; Custodio A; Tafuto S; La Casta A; Spada F; Lopez-Gonzalvez A; Gil-Calderon B; Espinosa-Olarte P; Barbas C; Garcia-Carbonero R; Soldevilla B
Eur J Endocrinol; 2024 Jan; 190(1):62-74. PubMed ID: 38033321
[TBL] [Abstract][Full Text] [Related]
29. A prospective cohort study of bladder cancer risk in relation to active cigarette smoking and household exposure to secondhand cigarette smoke.
Alberg AJ; Kouzis A; Genkinger JM; Gallicchio L; Burke AE; Hoffman SC; Diener-West M; Helzlsouer KJ; Comstock GW
Am J Epidemiol; 2007 Mar; 165(6):660-6. PubMed ID: 17204516
[TBL] [Abstract][Full Text] [Related]
30. Association of Smoking and Death from Genitourinary Malignancies: Analysis of the National Longitudinal Mortality Study.
Al Hussein Al Awamlh B; Shoag JE; Ravikumar V; Posada L; Taylor BL; van der Mijn JC; Khan AI; Fainberg J; Al Hussein Alawamlh O; Scherr DS
J Urol; 2019 Dec; 202(6):1248-1254. PubMed ID: 31290707
[TBL] [Abstract][Full Text] [Related]
31. The development of plasma pseudotargeted GC-MS metabolic profiling and its application in bladder cancer.
Zhou Y; Song R; Zhang Z; Lu X; Zeng Z; Hu C; Liu X; Li Y; Hou J; Sun Y; Xu C; Xu G
Anal Bioanal Chem; 2016 Sep; 408(24):6741-9. PubMed ID: 27473428
[TBL] [Abstract][Full Text] [Related]
32. Urinary metabolomic signature of muscle-invasive bladder cancer: A multiplatform approach.
Jacyna J; Wawrzyniak R; Balayssac S; Gilard V; Malet-Martino M; Sawicka A; Kordalewska M; Nowicki Ł; Kurek E; Bulska E; Patejko M; Markuszewski M; Gutknecht P; Matuszewski M; Siebert J; Kaliszan R; Markuszewski MJ
Talanta; 2019 Sep; 202():572-579. PubMed ID: 31171223
[TBL] [Abstract][Full Text] [Related]
33. Identification of Serum Markers of Esophageal Adenocarcinoma by Global and Targeted Metabolic Profiling.
Sanchez-Espiridion B; Liang D; Ajani JA; Liang S; Ye Y; Hildebrandt MA; Gu J; Wu X
Clin Gastroenterol Hepatol; 2015 Oct; 13(10):1730-1737.e9. PubMed ID: 25998788
[TBL] [Abstract][Full Text] [Related]
34. Knowledge of the harms of tobacco use among patients with bladder cancer.
Bassett JC; Gore JL; Kwan L; Ritch CR; Barocas DA; Penson DF; McCarthy WJ; Saigal CS
Cancer; 2014 Dec; 120(24):3914-22. PubMed ID: 25385059
[TBL] [Abstract][Full Text] [Related]
35. A novel clinical multidimensional transcriptome signature predicts prognosis in bladder cancer.
Liu CP; Zhang JH; Zheng SC; Liu J; Guo JC
Oncol Rep; 2018 Nov; 40(5):2826-2835. PubMed ID: 30226624
[TBL] [Abstract][Full Text] [Related]
36. NMR-based metabolomic analysis of human bladder cancer.
Cao M; Zhao L; Chen H; Xue W; Lin D
Anal Sci; 2012; 28(5):451-6. PubMed ID: 22687923
[TBL] [Abstract][Full Text] [Related]
37. Gender- and smoking-related bladder cancer risk.
Castelao JE; Yuan JM; Skipper PL; Tannenbaum SR; Gago-Dominguez M; Crowder JS; Ross RK; Yu MC
J Natl Cancer Inst; 2001 Apr; 93(7):538-45. PubMed ID: 11287448
[TBL] [Abstract][Full Text] [Related]
38. Establishment of the circadian metabolic phenotype strategy in spontaneously hypertensive rats: a dynamic metabolomics study.
Wang H; Wang X; Qi D; Sun M; Hou Q; Li Y; Jiang H
J Transl Med; 2020 Jan; 18(1):38. PubMed ID: 31992312
[TBL] [Abstract][Full Text] [Related]
39. Risk of bladder cancer by source and type of tobacco exposure: a case-control study.
Burch JD; Rohan TE; Howe GR; Risch HA; Hill GB; Steele R; Miller AB
Int J Cancer; 1989 Oct; 44(4):622-8. PubMed ID: 2793235
[TBL] [Abstract][Full Text] [Related]
40. Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy.
Rink M; Zabor EC; Furberg H; Xylinas E; Ehdaie B; Novara G; Babjuk M; Pycha A; Lotan Y; Trinh QD; Chun FK; Lee RK; Karakiewicz PI; Fisch M; Robinson BD; Scherr DS; Shariat SF
Eur Urol; 2013 Sep; 64(3):456-64. PubMed ID: 23206854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
